Literature DB >> 35307651

Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier.

Raymond K Hau1, Robert R Klein1, Stephen H Wright1, Nathan J Cherrington2.   

Abstract

The blood-testis barrier (BTB) is formed by basal tight junctions between adjacent Sertoli cells (SCs) of the seminiferous tubules and acts as a physical barrier to protect developing germ cells in the adluminal compartment from reproductive toxicants. Xenobiotics, including antivirals, male contraceptives, and cancer chemotherapeutics, are known to cross the BTB, although the mechanisms that permit barrier circumvention are generally unknown. This study used immunohistological staining of human testicular tissue to determine the site of expression for xenobiotic transporters that facilitate transport across the BTB. Organic anion transporter (OAT) 1, OAT2, and organic cation transporter, novel (OCTN) 1 primarily localized to the basal membrane of SCs, whereas OCTN2, multidrug resistance protein (MRP) 3, MRP6, and MRP7 localized to SC basal membranes and peritubular myoid cells (PMCs) surrounding the seminiferous tubules. Concentrative nucleoside transporter (CNT) 2 localized to Leydig cells (LCs), PMCs, and SC apicolateral membranes. Organic cation transporter (OCT) 1, OCT2, and OCT3 mostly localized to PMCs and LCs, although there was minor staining in developing germ cells for OCT3. Organic anion transporting polypeptide (OATP) 1A2, OATP1B1, OATP1B3, OATP2A1, OATP2B1, and OATP3A1-v2 localized to SC basal membranes with diffuse staining for some transporters. Notably, OATP1C1 and OATP4A1 primarily localized to LCs. Positive staining for multidrug and toxin extrusion protein (MATE) 1 was only observed throughout the adluminal compartment. Definitive staining for CNT1, OAT3, MATE2, and OATP6A1 was not observed. The location of these transporters is consistent with their involvement in the movement of xenobiotics across the BTB. Altogether, the localization of these transporters provides insight into the mechanisms of drug disposition across the BTB and will be useful in developing tools to overcome the pharmacokinetic and pharmacodynamic difficulties presented by the BTB. SIGNIFICANCE STATEMENT: Although the total mRNA and protein expression of drug transporters in the testes has been explored, the localization of many transporters at the blood-testis barrier (BTB) has not been determined. This study applied immunohistological staining in human testicular tissues to identify the cellular localization of drug transporters in the testes. The observations made in this study have implications for the development of drugs that can effectively use transporters expressed at the basal membranes of Sertoli cells to bypass the BTB.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35307651      PMCID: PMC9190233          DOI: 10.1124/dmd.121.000748

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.579


  104 in total

1.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 2.  TEER measurement techniques for in vitro barrier model systems.

Authors:  Balaji Srinivasan; Aditya Reddy Kolli; Mandy Brigitte Esch; Hasan Erbil Abaci; Michael L Shuler; James J Hickman
Journal:  J Lab Autom       Date:  2015-01-13

3.  An in vitro system to study Sertoli cell blood-testis barrier dynamics.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Methods Mol Biol       Date:  2011

4.  Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.

Authors:  K Fujiwara; H Adachi; T Nishio; M Unno; T Tokui; M Okabe; T Onogawa; T Suzuki; N Asano; M Tanemoto; M Seki; K Shiiba; M Suzuki; Y Kondo; K Nunoki; T Shimosegawa; K Iinuma; S Ito; S Matsuno; T Abe
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

5.  Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps).

Authors:  Xingguo Cheng; Jonathan Maher; Chuan Chen; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-04-20       Impact factor: 3.922

Review 6.  Emerging role for drug transporters at the blood-testis barrier.

Authors:  Dolores D Mruk; Linlin Su; C Yan Cheng
Journal:  Trends Pharmacol Sci       Date:  2010-12-17       Impact factor: 14.819

7.  Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.

Authors:  Guoqiang Zhang; Yanrong Ma; Dali Xi; Zhi Rao; Xiaohan Sun; Xin'an Wu
Journal:  Biopharm Drug Dispos       Date:  2018-12-18       Impact factor: 1.627

8.  Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.

Authors:  Atsushi Ose; Hiroyuki Kusuhara; Chihiro Endo; Kimio Tohyama; Mari Miyajima; Satoshi Kitamura; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

9.  Nucleoside transport at the blood-testis barrier studied with primary-cultured sertoli cells.

Authors:  Ryo Kato; Tomoji Maeda; Toshihiro Akaike; Ikumi Tamai
Journal:  J Pharmacol Exp Ther       Date:  2004-11-16       Impact factor: 4.030

10.  Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.

Authors:  Lenka Cervenkova; Ondrej Vycital; Jan Bruha; Jachym Rosendorf; Richard Palek; Vaclav Liska; Ondrej Daum; Beatrice Mohelnikova-Duchonova; Pavel Soucek
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

View more
  1 in total

1.  Physiological Characterization of the Transporter-Mediated Uptake of the Reversible Male Contraceptive H2-Gamendazole Across the Blood-Testis Barrier.

Authors:  Raymond K Hau; Joseph S Tash; Gunda I Georg; Stephen H Wright; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2022-07-02       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.